Skip to main content
SpringerLink
Log in

Other Genes Implicated in Alzheimer’s Disease

  • Chapter
  • First Online:
Genetic Variants in Alzheimer's Disease

  • 1246 Accesses

Abstract

Susceptibility to Alzheimer’s Disease (AD) most likely results from many genetic and environmental risk factors and their interplay. Apolipoprotein E (APOE) and the nine novel genetic risk loci identified from the recent genome-wide association studies (GWAS) account for a portion of the estimated genetic susceptibility to AD [1]. While it is possible that discovery of the actual functional genetic risk polymorphisms at these novel loci will help explain a larger fraction of the AD risk, the more likely scenario is the existence of many more AD risk genes. Indeed, hundreds of genes have been implicated in risk of AD, since the early 1990s [2]. Although some of these are likely false positive findings due to underpowered studies, others have arisen from well-powered studies, were replicated by some follow-up efforts and/or evaluated by supportive functional studies. In this chapter, we discuss examples of these “Other AD Genes.” The characterization of the complete list of such genes is beyond the scope of this chapter. As such, the main focus is on alternative strategies for genetic risk factor discovery with highlights of several genes per each approach discussed. Examples of genes identified via the earlier AD GWAS, quantitative endophenotype approaches, functional studies as well as next-generation sequencing (NGS) methodologies are evaluated in this chapter. Identification of the functional variants, additional replication, and further biological investigations are required for widespread acceptance of these as AD risk genes. Nonetheless, this chapter emphasizes the potential utility of alternative approaches besides large disease GWAS in genetic risk discovery for complex diseases like AD. Ultimately multiple complementary research paradigms will be required to uncover the complete genetic risk structure of AD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Naj AC et al (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet 43(5):436–441

    PubMed  CAS  Google Scholar 

  2. Ertekin-Taner N (2007) Genetics of Alzheimer’s disease: a centennial review. Neurol Clin 25(3):611–667

    PubMed  Google Scholar 

  3. Grupe A et al (2007) Evidence for novel susceptibility genes for late-onset Alzheimer’s disease from a genome-wide association study of putative functional variants. Hum Mol Genet 16(8):865–873

    PubMed  CAS  Google Scholar 

  4. Coon KD et al (2007) A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer’s disease. J Clin Psychiatry 68(4):613–618

    PubMed  CAS  Google Scholar 

  5. Reiman EM et al (2007) GAB2 alleles modify Alzheimer’s risk in APOE epsilon4 carriers. Neuron 54(5):713–720

    PubMed  CAS  Google Scholar 

  6. Li H et al (2008) Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 65(1):45–53

    PubMed  Google Scholar 

  7. Abraham R et al (2008) A genome-wide association study for late-onset Alzheimer’s disease using DNA pooling. BMC Med Genomics 1:44

    PubMed  Google Scholar 

  8. Bertram L et al (2008) Genome-wide association analysis reveals putative Alzheimer’s disease susceptibility loci in addition to APOE. Am J Hum Genet 83(5):623–632

    PubMed  CAS  Google Scholar 

  9. Beecham GW et al (2009) Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet 84(1):35–43

    PubMed  CAS  Google Scholar 

  10. Feulner TM et al (2009) Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry 15(7):756–766

    PubMed  Google Scholar 

  11. Poduslo SE et al (2009) Genome screen of late-onset Alzheimer’s extended pedigrees identifies TRPC4AP by haplotype analysis. Am J Med Genet B Neuropsychiatr Genet 150B(1):50–55

    PubMed  CAS  Google Scholar 

  12. Carrasquillo MM et al (2009) Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer’s disease. Nat Genet 41(2):192–198

    PubMed  CAS  Google Scholar 

  13. Ertekin-Taner N (2010) Genetics of Alzheimer disease in the pre- and post-GWAS era. Alzheimers Res Ther 2(1):3

    PubMed  Google Scholar 

  14. Harold D et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet 41(10):1088–1093

    PubMed  CAS  Google Scholar 

  15. Lambert JC et al (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet 41(10):1094–1099

    PubMed  CAS  Google Scholar 

  16. Seshadri S et al (2010) Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303(18):1832–1840

    PubMed  CAS  Google Scholar 

  17. Hollingworth P et al (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 43(5):429–435

    PubMed  CAS  Google Scholar 

  18. Lang R, Gundlach AL, Kofler B (2007) The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther 115(2):177–207

    PubMed  CAS  Google Scholar 

  19. Lawrence C, Fraley GS (2011) Galanin-like peptide (GALP) is a hypothalamic regulator of energy homeostasis and reproduction. Front Neuroendocrinol 32(1):1–9

    PubMed  CAS  Google Scholar 

  20. Shulman JM et al (2010) Intermediate phenotypes identify divergent pathways to Alzheimer’s disease. PLoS One 5(6):e11244

    PubMed  Google Scholar 

  21. Beale EG et al (2004) Disregulated glyceroneogenesis: PCK1 as a candidate diabetes and obesity gene. Trends Endocrinol Metab 15(3):129–135

    PubMed  CAS  Google Scholar 

  22. Hanson RW (2009) Thematic minireview series: a perspective on the biology of phosphoenolpyruvate carboxykinase 55 years after its discovery. J Biol Chem 284(40):27021–27023

    PubMed  CAS  Google Scholar 

  23. Gouda HN et al (2010) The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol 171(6):645–655

    PubMed  Google Scholar 

  24. Landreth G et al (2008) PPARgamma agonists as therapeutics for the treatment of Alzheimer’s disease. Neurotherapeutics 5(3):481–489

    PubMed  CAS  Google Scholar 

  25. Xia Z et al (2010) A putative Alzheimer’s disease risk allele in PCK1 influences brain atrophy in multiple sclerosis. PLoS One 5(11):e14169

    PubMed  CAS  Google Scholar 

  26. Azoitei N et al (2007) Thirty-eight-negative kinase 1 (TNK1) facilitates TNFalpha-induced apoptosis by blocking NF-kappaB activation. Oncogene 26(45):6536–6545

    PubMed  CAS  Google Scholar 

  27. May WS et al (2010) Tnk1/Kos1: a novel tumor suppressor. Trans Am Clin Climatol Assoc 121:281–292; discussion 292–293

    PubMed  Google Scholar 

  28. Gu H, Neel BG (2003) The “Gab” in signal transduction. Trends Cell Biol 13(3):122–130

    PubMed  CAS  Google Scholar 

  29. Bentires-Alj M et al (2006) A role for the scaffolding adapter GAB2 in breast cancer. Nat Med 12(1):114–121

    PubMed  CAS  Google Scholar 

  30. Liang WS et al (2011) Association between GAB2 haplotype and higher glucose metabolism in Alzheimer’s disease-affected brain regions in cognitively normal APOEepsilon4 carriers. Neuroimage 54(3):1896–1902

    PubMed  CAS  Google Scholar 

  31. Hibar DP et al (2011) Voxelwise gene-wide association study (vGeneWAS): multivariate gene-based association testing in 731 elderly subjects. Neuroimage 56(4):1875–1891

    PubMed  Google Scholar 

  32. Hibar DP et al (2012) Alzheimer’s disease risk gene, GAB2, is associated with regional brain volume differences in 755 young healthy twins. Twin Res Hum Genet 15(3):286–295

    PubMed  Google Scholar 

  33. Kim HJ et al (2012) Golgi phosphoprotein 2 in physiology and in diseases. Cell Biosci 2(1):31

    PubMed  CAS  Google Scholar 

  34. Zhou Y et al (2011) Golgi phosphoprotein 2 (GOLPH2/GP73/GOLM1) interacts with secretory clusterin. Mol Biol Rep 38(3):1457–1462

    PubMed  CAS  Google Scholar 

  35. Inkster B et al (2012) Genetic variation in GOLM1 and prefrontal cortical volume in Alzheimer’s disease. Neurobiol Aging 33(3):457–465

    PubMed  CAS  Google Scholar 

  36. Shudo K et al (2009) Towards retinoid therapy for Alzheimer’s disease. Curr Alzheimer Res 6(3):302–311

    PubMed  CAS  Google Scholar 

  37. Cramer PE et al (2012) ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335(6075):1503–1506

    PubMed  CAS  Google Scholar 

  38. Lupo A et al (2011) ZNF224: structure and role of a multifunctional KRAB-ZFP protein. Int J Biochem Cell Biol 43(4):470–473

    PubMed  CAS  Google Scholar 

  39. Porteous DJ et al (2011) DISC1 at 10: connecting psychiatric genetics and neuroscience. Trends Mol Med 17(12):699–706

    PubMed  CAS  Google Scholar 

  40. Inestrosa NC, Montecinos-Oliva C, Fuenzalida M (2012) Wnt signaling: role in Alzheimer disease and schizophrenia. J Neuroimmune Pharmacol 7(4):788–807

    PubMed  Google Scholar 

  41. Blanco P et al (2000) Conservation of PCDHX in mammals; expression of human X/Y genes predominantly in brain. Mamm Genome 11(10):906–914

    PubMed  CAS  Google Scholar 

  42. Blanco-Arias P, Sargent CA, Affara NA (2004) Protocadherin X ( PCDHX) and Y ( PCDHY) genes; multiple mRNA isoforms encoding variant signal peptides and cytoplasmic domains. Mamm Genome 15(1):41–52

    PubMed  CAS  Google Scholar 

  43. Durand CM et al (2006) Expression and genetic variability of PCDH11Y, a gene specific to Homo sapiens and candidate for susceptibility to psychiatric disorders. Am J Med Genet B Neuropsychiatr Genet 141B(1):67–70

    PubMed  CAS  Google Scholar 

  44. Senzaki K, Ogawa M, Yagi T (1999) Proteins of the CNR family are multiple receptors for Reelin. Cell 99(6):635–647

    PubMed  CAS  Google Scholar 

  45. Haas IG et al (2005) Presenilin-dependent processing and nuclear function of gamma-protocadherins. J Biol Chem 280(10):9313–9319

    PubMed  CAS  Google Scholar 

  46. Sieprath T, Darwiche R, De Vos WH (2012) Lamins as mediators of oxidative stress. Biochem Biophys Res Commun 421(4):635–639

    PubMed  CAS  Google Scholar 

  47. Cluett C et al (2010) Polymorphisms in LMNA and near a SERPINA gene cluster are associated with cognitive function in older people. Neurobiol Aging 31(9):1563–1568

    PubMed  CAS  Google Scholar 

  48. Gottesman II, Gould TD (2003) The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160(4):636–645

    PubMed  Google Scholar 

  49. Glahn DC, Thompson PM, Blangero J (2007) Neuroimaging endophenotypes: strategies for finding genes influencing brain structure and function. Hum Brain Mapp 28(6):488–501

    PubMed  Google Scholar 

  50. Ertekin-Taner N (2011) Gene expression endophenotypes: a novel approach for gene discovery in Alzheimer’s disease. Mol Neurodegener 6(1):31

    PubMed  CAS  Google Scholar 

  51. Kramer PL et al (2010) Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study. Neurobiol Aging 32(12):2113–2122

    PubMed  Google Scholar 

  52. Stein JL et al (2012) Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet 44(5):552–561

    PubMed  CAS  Google Scholar 

  53. Ikram MA et al (2012) Common variants at 6q22 and 17q21 are associated with intracranial volume. Nat Genet 44(5):539–544

    PubMed  CAS  Google Scholar 

  54. Kim S et al (2011) Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 76(1):69–79

    PubMed  CAS  Google Scholar 

  55. Guerreiro R et al (2013) TREM2 variants in Alzheimer’s disease. N Engl J Med 368(2):117–127

    PubMed  CAS  Google Scholar 

  56. Jonsson T et al (2013) Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med 368(2):107–116

    PubMed  CAS  Google Scholar 

  57. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239–259

    PubMed  CAS  Google Scholar 

  58. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580):353–356

    PubMed  CAS  Google Scholar 

  59. Scheuner D et al (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 2(8):864–870

    PubMed  CAS  Google Scholar 

  60. Fleisher AS et al (2012) Florbetapir PET analysis of amyloid-beta deposition in the presenilin 1 E280A autosomal dominant Alzheimer’s disease kindred: a cross-sectional study. Lancet Neurol 11(12):1057–1065

    PubMed  CAS  Google Scholar 

  61. Ertekin-Taner N et al (2008) Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology 70(8):596–606

    PubMed  CAS  Google Scholar 

  62. Ertekin-Taner N et al (2001) Heritability of plasma amyloid beta in typical late-onset Alzheimer’s disease pedigrees. Genet Epidemiol 21(1):19–30

    PubMed  CAS  Google Scholar 

  63. Ertekin-Taner N et al (2000) Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer’s disease pedigrees. Science 290(5500):2303–2304

    PubMed  CAS  Google Scholar 

  64. Myers A et al (2000) Susceptibility locus for Alzheimer’s disease on chromosome 10. Science 290(5500):2304–2305

    PubMed  CAS  Google Scholar 

  65. Ertekin-Taner N et al (2003) Fine mapping of the alpha-T catenin gene to a quantitative trait locus on chromosome 10 in late-onset Alzheimer’s disease pedigrees. Hum Mol Genet 12(23):3133–3143

    PubMed  CAS  Google Scholar 

  66. Smith JD et al (2011) Alpha T-catenin (CTNNA3): a gene in the hand is worth two in the nest. Cell Mol Life Sci 68(15):2493–2498

    PubMed  CAS  Google Scholar 

  67. Zhang Z et al (1998) Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 395(6703):698–702

    PubMed  CAS  Google Scholar 

  68. Bertram L et al (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39(1):17–23

    PubMed  CAS  Google Scholar 

  69. Linhoff MW et al (2009) An unbiased expression screen for synaptogenic proteins identifies the LRRTM protein family as synaptic organizers. Neuron 61(5):734–749

    PubMed  CAS  Google Scholar 

  70. Majercak J et al (2006) LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer’s disease. Proc Natl Acad Sci USA 103(47):17967–17972

    PubMed  CAS  Google Scholar 

  71. Martin ER et al (2005) Interaction between the alpha-T catenin gene (VR22) and APOE in Alzheimer’s disease. J Med Genet 42(10):787–792

    PubMed  CAS  Google Scholar 

  72. Bertram L et al (2000) Evidence for genetic linkage of Alzheimer’s disease to chromosome 10q. Science 290(5500):2302–2303

    PubMed  CAS  Google Scholar 

  73. Nalivaeva NN et al (2012) Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease? J Neurochem 120(Suppl 1):167–185

    PubMed  CAS  Google Scholar 

  74. Ertekin-Taner N et al (2004) Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Abeta42 levels and risk for Alzheimer disease. Hum Mutat 23(4):334–342

    PubMed  CAS  Google Scholar 

  75. Reitz C et al (2012) Association between variants in IDE-KIF11-HHEX and plasma amyloid beta levels. Neurobiol Aging 33(1):199.e13–7

    CAS  Google Scholar 

  76. Blomqvist ME et al (2005) Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer’s disease brain. Neurobiol Aging 26(6):795–802

    PubMed  CAS  Google Scholar 

  77. Zou F et al (2010) Gene expression levels as endophenotypes in genome-wide association studies of Alzheimer disease. Neurology 74(6):480–486

    PubMed  CAS  Google Scholar 

  78. Carrasquillo MM et al (2010) Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Abeta, and Alzheimer’s disease. PLoS One 5(1):e8764

    PubMed  Google Scholar 

  79. Kauwe JSK et al (2009) Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics 10(1):13–17

    PubMed  CAS  Google Scholar 

  80. Allen M et al (2012) Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology 79(3):221–228

    PubMed  CAS  Google Scholar 

  81. Zou F et al (2012) Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS Genet 8(6):e1002707

    PubMed  CAS  Google Scholar 

  82. Ling IF et al (2012) Genetics of clusterin isoform expression and Alzheimer’s disease risk. PLoS One 7(4):e33923

    PubMed  CAS  Google Scholar 

  83. Pittman AM, Fung HC, de Silva R (2006) Untangling the tau gene association with neurodegenerative disorders. Hum Mol Genet 15(Spec No 2):R188–R195

    PubMed  CAS  Google Scholar 

  84. Myers AJ et al (2007) A survey of genetic human cortical gene expression. Nat Genet 39(12):1494–1499

    PubMed  CAS  Google Scholar 

  85. Myers AJ et al (2007) The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis 25(3):561–570

    PubMed  CAS  Google Scholar 

  86. McKhann G et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34(7):939–944

    PubMed  CAS  Google Scholar 

  87. Jack CR Jr et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 9(1):119–128

    PubMed  CAS  Google Scholar 

  88. Papassotiropoulos A et al (2006) Common Kibra alleles are associated with human memory performance. Science 314(5798):475–478

    PubMed  CAS  Google Scholar 

  89. Burgess JD et al (2010) Association of common KIBRA variants with episodic memory and AD risk. Neurobiol Aging 32(3):557.e1–9

    Google Scholar 

  90. Makuch L et al (2011) Regulation of AMPA receptor function by the human memory-associated gene KIBRA. Neuron 71(6):1022–1029

    PubMed  CAS  Google Scholar 

  91. Dreses-Werringloer U et al (2008) A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer’s disease risk. Cell 133(7):1149–1161

    PubMed  CAS  Google Scholar 

  92. Ma Z et al (2012) Calcium homeostasis modulator 1 (CALHM1) is the pore-forming subunit of an ion channel that mediates extracellular Ca2+ regulation of neuronal excitability. Proc Natl Acad Sci USA 109(28):E1963–E1971

    PubMed  CAS  Google Scholar 

  93. Lambert JC et al (2010) The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer’s disease: a meta-analysis study. J Alzheimers Dis 22(1):247–255

    PubMed  CAS  Google Scholar 

  94. Kauwe JS et al (2010) Validating predicted biological effects of Alzheimer’s disease associated SNPs using CSF biomarker levels. J Alzheimers Dis 21(3):833–842

    PubMed  CAS  Google Scholar 

  95. Koppel J et al (2011) CALHM1 P86L polymorphism modulates CSF Abeta levels in cognitively healthy individuals at risk for Alzheimer’s disease. Mol Med 17(9–10):974–979

    PubMed  CAS  Google Scholar 

  96. Rogaeva E et al (2007) The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 39(2):168–177

    PubMed  CAS  Google Scholar 

  97. Reitz C et al (2011) Meta-analysis of the association between variants in SORL1 and Alzheimer disease. Arch Neurol 68(1):99–106

    PubMed  Google Scholar 

  98. TCuenco K et al (2008) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease. Arch Neurol 65(12):1640–1648

    Google Scholar 

  99. Kolsch H et al (2008) Influence of SORL1 gene variants: association with CSF amyloid-beta products in probable Alzheimer’s disease. Neurosci Lett 440(1):68–71

    PubMed  Google Scholar 

  100. Seshadri S et al (2007) Genetic correlates of brain aging on MRI and cognitive test measures: a genome-wide association and linkage analysis in the Framingham Study. BMC Med Genet 8(Suppl 1):S15

    PubMed  Google Scholar 

  101. Jin SC et al (2012) Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer’s disease Ibero-American cohort. Alzheimers Res Ther 4(4):34

    PubMed  CAS  Google Scholar 

  102. Bouchon A, Dietrich J, Colonna M (2000) Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 164(10):4991–4995

    PubMed  CAS  Google Scholar 

  103. Paloneva J et al (2003) DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J Exp Med 198(4):669–675

    PubMed  CAS  Google Scholar 

  104. Neumann H, Takahashi K (2007) Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis. J Neuroimmunol 184(1–2):92–99

    PubMed  CAS  Google Scholar 

  105. Takahashi K, Rochford CD, Neumann H (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 201(4):647–657

    PubMed  CAS  Google Scholar 

  106. Melchior B et al (2010) Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer’s disease. ASN Neuro 2(3):e00037

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, FL, 32224, USA

    Minerva M. Carrasquillo Ph.D. & Mariet Allen Ph.D.

  2. Departments of Neurology and Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, FL, 32224, USA

    Nilüfer Ertekin-Taner M.D., Ph.D.

Authors
  1. Minerva M. Carrasquillo Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mariet Allen Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nilüfer Ertekin-Taner M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nilüfer Ertekin-Taner M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Queen's Medical Centre, School of Molecular Medical Sciences, University of Nottingham, Hucknall Road, Nottingham, NG7 2UH, United Kingdom

    Kevin Morgan

  2. , Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, 32224, USA

    Minerva M. Carrasquillo

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Carrasquillo, M.M., Allen, M., Ertekin-Taner, N. (2013). Other Genes Implicated in Alzheimer’s Disease. In: Morgan, K., Carrasquillo, M. (eds) Genetic Variants in Alzheimer's Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7309-1_12

Download citation

Publish with us

Policies and ethics

Search

Navigation